Combination of CTLA-4 and PD-1 blockers for treatment of cancer
A Rotte - Journal of Experimental & Clinical Cancer Research, 2019 - Springer
Targeting checkpoints of immune cell activation has been demonstrated to be the most
effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte …
effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte …
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
C Chen, L **e, T Ren, Y Huang, J Xu, W Guo - Cancer letters, 2021 - Elsevier
Osteosarcoma (OS) is the most common primary malignancy of the bone and has a high
propensity for local invasion and metastasis. Although combining surgery with …
propensity for local invasion and metastasis. Although combining surgery with …
B cells are associated with survival and immunotherapy response in sarcoma
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …
histological subtypes,. The clinical presentation of patients with different subtypes is often …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
Soft‐tissue sarcoma in adults: an update on the current state of histiotype‐specific management in an era of personalized medicine
AC Gamboa, A Gronchi… - CA: a cancer journal for …, 2020 - Wiley Online Library
Soft‐tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies,
with over 100 different histologic subtypes occurring predominately in the trunk, extremity …
with over 100 different histologic subtypes occurring predominately in the trunk, extremity …
Advances on immunotherapy for osteosarcoma
S Yu, X Yao - Molecular Cancer, 2024 - Springer
Osteosarcoma is the most common primary bone cancer in children and young adults.
Limited progress has been made in improving the survival outcomes in patients with …
Limited progress has been made in improving the survival outcomes in patients with …
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …
precision-based therapeutics for these cancers. Prospective comprehensive genomic …
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Osteosarcoma, with poor survival after metastasis, is considered the most common primary
bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival …
bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival …
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the
identification of therapeutic targets, clinical research, and advancing patient care. Because …
identification of therapeutic targets, clinical research, and advancing patient care. Because …
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Background VEGF promotes an immunosuppressive microenvironment and contributes to
immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the …
immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the …